The Clinical Research Department at BC Cancer was established to be the central point of contact for investigators wanting to undertake clinical research at BC Cancer. 

The goals of the department are to improve the quality and productivity of clinical research at BC Cancer while encouraging a culture of innovation, responsibility and accountability.  The Clinical Research Department is committed to ensuring BC Cancer clinical research is operationally efficient and of high quality.  We will achieve this by standardizing practices across the province, providing comprehensive education programs and quality and metrics reporting and administrative support for clinician-investigators.

From Research to Treatment

Many of the treatments we have in Canada today are available thanks to people who volunteer to take part in a clinical trial​.  
Find out more about clinical trials

News & Events

Improving health outcomes in breast radiotherapy: A universal solution for every body

For patients undergoing breast radiotherapy to treat their cancer, receiving a high-quality standard of care is important – particularly given they receive treatment over several sessions. 

However, this consistency can be challenging to maintain as each patient’s body is different. Positioning the breast accurately is key to ensuring the radiation targets the right area, yet variations in body shape and size can make this difficult. 

Small centre, big Impact: Prince George clinicians co-author three Lancet Oncology papers

Investigators from BC Cancer – Prince George (Centre for the North) are co-authors on three international collaborative publications featured in the same issue of The Lancet Oncology. These papers reflect the centre’s engagement in global research collaborations that shape how cancer care is studied, reported, and delivered.

 

Blood test expands access to FGFR-targeted therapy for metastatic urothelial cancer

Researchers at BC Cancer Research Institute, led by Dr. Bernie Eigl, director of the Provincial Clinical Trials Office, and Dr. Alex Wyatt, senior scientist and scientific director of the Cancer Genetics and Genomics Laboratory, examined whether a blood test that analyzes cancer-derived DNA found in the blood, called circulating tumour DNA (ctDNA), could help identify more patients with metastatic urothelial carcinoma – an aggressive form of bladder cancer – who are eligible for FGFR-targeted therapy.

Recent Publications

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

Lancet Oncol 2026
Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, Livi L, Tran P, Corn PG, Aparicio A, Simontacchi G, Kiess AP, Wang JH, Fonteyne V, Bultijnck R, Phillips R, Deek MP, Olson R, Harrow S, Marvaso G, Lorubbio C, Jereczek-Fossa BA, Ludmir EB, Blanchard P, Warner A, Sun R, Palma DA, Ost P
Learn More
Back to top